Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis

被引：37

作者：

Petrelli, Fausto ^{[1
]}

Ferrara, Roberto ^{[2
]}

Signorelli, Diego ^{[2
]}

Ghidini, Antonio ^{[3
]}

Proto, Claudia ^{[2
]}

Roudi, Raheleh ^{[4
]}

Sabet, Mehrdad N. ^{[5
]}

Facelli, Sara ^{[6
]}

Garassino, Marina C. ^{[2
]}

Luciani, Andrea ^{[1
]}

Roviello, Giandomenico ^{[7
]}

机构：

[1] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy

[3] Casa Cura Igea, Med Oncol Unit, I-20126 Milan, Italy

[4] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA

[5] Minist Hlth & Med Educ, Canc Epidemiol Res & Treatment Ctr, Tehran, Iran

[6] Univ Florence, Sch Human Hlth Sci, Largo Brambilla 3, I-50134 Florence, Italy

[7] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 07期

关键词：

chemotherapy; combinations; first-line; immune checkpoint inhibitors; meta-analysis; non-small-cell lung cancer; PD-1; PD-L1; randomized trials; survival; CELL LUNG-CANCER; CARBOPLATIN; COMBINATION; PACLITAXEL; IPILIMUMAB; PEMBROLIZUMAB; ATEZOLIZUMAB; EFFICACY; ONCOLOGY; THERAPY;

D O I：

10.2217/imt-2020-0224

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Lay abstract We provide a meta-analysis of randomized controlled trials in first-line studies where immune checkpoint inhibitors were added to chemotherapy (CT) and were compared with CT alone. Nine articles were included for qualitative and quantitative synthesis. A meta-analysis of the nine randomized trials indicated a significant benefit in terms of overall survival (OS; hazard ratio: 0.75 [95% CI: 0.66-0.85]; p < 0.01). Only programmed death ligand-1 positive-high cancers were observed to receive a significant OS benefit. In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to CT may improve OS as compared with CT alone. This study is a meta-analysis of randomized controlled trials involving first-line studies in which immune checkpoint inhibitors were added to chemotherapy and were compared with chemotherapy alone. The primary end point was overall survival (OS). The analyses used random-effects models and the Grading of Recommendations Assessment, Development, and Evaluation system to rate the quality of the evidence. Nine articles were included for qualitative and quantitative synthesis. A meta-analysis of the nine randomized trials showed a significant benefit in terms of OS (hazard ratio: 0.75 [95% CI: 0.66-0.85]; p < 0.01). Only programmed death ligand-1 positive-high cancers derive a significant OS benefit. In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to chemotherapy may improve both OS compared with chemotherapy alone.

引用

页码：621 / 632

页数：12

共 35 条

[11] Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer [J].

Govindan, Ramaswamy ;

Szczesna, Aleksandra ;

Ahn, Myung-Ju ;

Schneider, Claus-Peter ;

Gonzalez Mella, Pablo Fernando ;

Barlesi, Fabrice ;

Han, Baohui ;

Ganea, Doina Elena ;

Von Pawel, Joachim ;

Vladimirov, Vladimir ;

Fadeeva, Natalia ;

Lee, Ki Hyeong ;

Kurata, Takayasu ;

Zhang, Li ;

Tamura, Tomohide ;

Postmus, Pieter E. ;

Jassem, Jacek ;

O'Byrne, Kenneth ;

Kopit, Justin ;

Li, Mingshun ;

Tschaika, Marina ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3449-+

[12] Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Hanna, Nasser ;

Johnson, David ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Giaccone, Giuseppe ;

Hesketh, Paul J. ;

Jaiyesimi, Ishmael ;

Leighl, Natasha B. ;

Riely, Gregory J. ;

Schiller, Joan H. ;

Schneider, Bryan J. ;

Smith, Thomas J. ;

Tashbar, Joan ;

Biermann, William A. ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3484-+

[13]

Higgins J., 2008, Cochrane Handbook for Systematic Reviews of Interventions, DOI [DOI 10.1002/9780470712184, 10.1002/9780470712184]

[14] Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial [J].

Jotte, Robert ;

Cappuzzo, Federico ;

Vynnychenko, Ihor ;

Stroyakovskiy, Daniil ;

Rodriguez-Abreu, Delvys ;

Hussein, Maen ;

Soo, Ross ;

Conter, Henry J. ;

Kozuki, Toshiyuki ;

Huang, Kuan-Chieh ;

Graupner, Vilma ;

Sun, Shawn W. ;

Hoang, Tien ;

Jessop, Helen ;

McCleland, Mark ;

Ballinger, Marcus ;

Sandler, Alan ;

Socinski, Mark A. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (08) :1351-1360

[15] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer [J].

Khunger, Monica ;

Rakshit, Sagar ;

Pasupuleti, Vinay ;

Hernandez, Adrian V. ;

Mazzone, Peter ;

Stevenson, James ;

Pennell, Nathan A. ;

Velcheti, Vamsidhar .

CHEST, 2017, 152 (02) :271-281

[16] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study [J].

Lynch, Thomas J. ;

Bondarenko, Igor ;

Luft, Alexander ;

Serwatowski, Piotr ;

Barlesi, Fabrice ;

Chacko, Raju ;

Sebastian, Martin ;

Neal, Joel ;

Lu, Haolan ;

Cuillerot, Jean-Marie ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2046-2054

[17] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry [J].

Mazieres, J. ;

Drilon, A. ;

Lusque, A. ;

Mhanna, L. ;

Cortot, A. B. ;

Mezquita, L. ;

Thai, A. A. ;

Mascaux, C. ;

Couraud, S. ;

Veillon, R. ;

Van Den Heuvel, M. ;

Neal, J. ;

Peled, N. ;

Fruh, M. ;

Ng, T. L. ;

Gounant, V ;

Popat, S. ;

Diebold, J. ;

Sabari, J. ;

Zhu, V. W. ;

Rothschild, S. I. ;

Bironzo, P. ;

Martinez-Marti, A. ;

Curioni-Fontecedro, A. ;

Rosell, R. ;

Lattuca-Truc, M. ;

Wiesweg, M. ;

Besse, B. ;

Solomon, B. ;

Barlesi, F. ;

Schouten, R. D. ;

Wakelee, H. ;

Camidge, D. R. ;

Zalcman, G. ;

Novello, S. ;

Ou, S. I. ;

Milia, J. ;

Gautschi, O. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1321-1328

[18]

Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535]

[19]

National Comprehensive Cancer Network [NCCN], 2019, Clinical Practice guidelines in oncology: antiemesis, P2019

[20] Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy [J].

Nosrati, Adi ;

Tsai, Katy K. ;

Goldinger, Simone M. ;

Tumeh, Paul ;

Grimes, Barbara ;

Loo, Kimberly ;

Algazi, Alain P. ;

Thi Dan Linh Nguyen-Kim ;

Levesque, Mitchell ;

Dummer, Reinhard ;

Hamid, Omid ;

Daud, Adil .

BRITISH JOURNAL OF CANCER, 2017, 116 (09) :1141-1147

← 1 2 3 4 →